Identification of an apolipoprotein(e) variant associated with type III hyperlipoproteinaemia in an indigenous Australian.
As a result of testing for lipid and apolipoprotein(e) (apo E) phenotype status of an indigenous Australian community, an apo E variant associated with type III hyperlipoproteinaemia has been identified. Apo E phenotype was determined by analysis of VLDL by isoelectric focusing, and genotype on DNA amplified by polymerase chain reaction, using two different restriction enzyme isotyping assays. Phenotypes and genotypes were discordant in samples from two subjects and an abnormal-sized restriction fragment was also observed in their genotyping gel patterns. DNA sequencing studies revealed this was due to a single nucleotide deletion, 3817delC, at amino acid 136 on apo E. This resulted in a new reading frame and the premature termination of the apo E protein due to a stop codon (TGA) at nucleotide 4105. The variant apo E null allele showed a recessive mode of inheritance and, in combination with the E2 allele, resulted in the type III hyperlipoproteinaemic phenotype but when inherited with the E4 allele had no marked effect on plasma lipids.
Department of Chemical Pathology, Princess Alexandra Hospital, Brisbane, Queensland, Australia. jill_tate@health.qld.gov.au
J R
JR
Tate
M M
MM
Hoffmann
P K
PK
Lovelock
J B
JB
Kesting
J T
JT
Shaw
D000293:Adolescent; D000328:Adult; D001057:Apolipoproteins E / Q000235:genetics* / Q000378:metabolism; D001483:Base Sequence / Q000235:genetics*; D005260:Female; D014644:Genetic Variation; D005838:Genotype; D006801:Humans; D006952:Hyperlipoproteinemia Type III / Q000235:genetics* / Q000378:metabolism; D008297:Male; D008875:Middle Aged
D001057:Apolipoproteins E